PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Janux Therapeutics, Inc. (JANX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US47103J1051

CUSIP

47103J105

Sector

Healthcare

IPO Date

Jun 11, 2021

Highlights

Market Cap

$1.75B

EPS (TTM)

-$1.28

Total Revenue (TTM)

$9.34M

Gross Profit (TTM)

$8.83M

EBITDA (TTM)

-$77.16M

Year Range

$22.52 - $71.71

Target Price

$85.33

Short %

30.30%

Short Ratio

11.98

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
JANX vs. NVDA JANX vs. USLM JANX vs. VKTX
Popular comparisons:
JANX vs. NVDA JANX vs. USLM JANX vs. VKTX

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Janux Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%NovemberDecember2025FebruaryMarchApril
18.05%
24.37%
JANX (Janux Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Janux Therapeutics, Inc. had a return of -44.55% year-to-date (YTD) and -39.22% in the last 12 months.


JANX

YTD

-44.55%

1M

-3.95%

6M

-40.66%

1Y

-39.22%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-10.18%

1M

-6.92%

6M

-9.92%

1Y

5.42%

5Y*

12.98%

10Y*

9.70%

*Annualized

Monthly Returns

The table below presents the monthly returns of JANX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-18.79%-24.36%-17.91%9.96%-44.55%
2024-20.22%465.19%-22.18%51.39%-6.14%-21.70%-3.08%15.71%-3.30%18.84%-16.26%18.43%398.97%
202368.64%-25.12%-27.24%26.61%-24.15%2.15%17.94%-21.43%-8.36%-36.31%35.98%22.91%-18.53%
2022-22.81%13.46%-17.01%-31.38%13.11%9.70%1.72%-12.88%25.14%33.53%-24.56%-3.45%-33.25%
2021-0.80%29.98%5.15%-36.57%12.58%-26.98%10.97%-21.55%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of JANX is 24, meaning it’s performing worse than 76% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of JANX is 2424
Overall Rank
The Sharpe Ratio Rank of JANX is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of JANX is 2626
Sortino Ratio Rank
The Omega Ratio Rank of JANX is 2929
Omega Ratio Rank
The Calmar Ratio Rank of JANX is 1414
Calmar Ratio Rank
The Martin Ratio Rank of JANX is 2323
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Janux Therapeutics, Inc. (JANX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for JANX, currently valued at -0.50, compared to the broader market-2.00-1.000.001.002.003.00
JANX: -0.50
^GSPC: 0.24
The chart of Sortino ratio for JANX, currently valued at -0.49, compared to the broader market-6.00-4.00-2.000.002.004.00
JANX: -0.49
^GSPC: 0.47
The chart of Omega ratio for JANX, currently valued at 0.95, compared to the broader market0.501.001.502.00
JANX: 0.95
^GSPC: 1.07
The chart of Calmar ratio for JANX, currently valued at -0.64, compared to the broader market0.001.002.003.004.00
JANX: -0.64
^GSPC: 0.24
The chart of Martin ratio for JANX, currently valued at -1.20, compared to the broader market-5.000.005.0010.0015.0020.00
JANX: -1.20
^GSPC: 1.08

The current Janux Therapeutics, Inc. Sharpe ratio is -0.50. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Janux Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.50
0.24
JANX (Janux Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Janux Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%NovemberDecember2025FebruaryMarchApril
-55.58%
-14.02%
JANX (Janux Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Janux Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Janux Therapeutics, Inc. was 83.14%, occurring on Nov 9, 2023. Recovery took 73 trading sessions.

The current Janux Therapeutics, Inc. drawdown is 55.58%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-83.14%Aug 6, 2021570Nov 9, 202373Feb 27, 2024643
-64.4%Dec 5, 202484Apr 8, 2025
-45.52%May 6, 202465Aug 7, 202483Dec 4, 2024148
-29.41%Feb 28, 202427Apr 5, 20244Apr 11, 202431
-26.12%Jun 14, 20212Jun 15, 202110Jun 29, 202112

Volatility

Volatility Chart

The current Janux Therapeutics, Inc. volatility is 21.21%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
21.21%
13.60%
JANX (Janux Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Janux Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Janux Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab